Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 13 (3), 300-308, 2012-03
Elsevier BV